Abbott Labs Sells Developed Markets Generics Unit

July 14 (Bloomberg) -- Marshall Sonenshine, chairman and managing partner at Sonenshine Partners, and Jonathan Golub, chief U.S. market strategist at RBC Capital Markets, examine Abbott Laboratories selling its developed markets generic drug unit to Mylan in a deal worth $5.3 Billion and what it means to the current M&A market. They speak on “Bloomberg Surveillance.”
Samsung Challenges Apple With S6, Mobile Wallet
18:36 - March 2 -- Samsung Electronics rebooted its premium Galaxy smartphone line with the S6 and S6 Edge, featuring a three-sided screen, as the South Korean company tries to reverse profit declines and market-share losses to Apple. Bloomberg's Zeb Eckert has more on "First Up."
  • PBOC Cuts Rates for Second Time in Three Months
  • The Top Stocks to Watch in Asia Today
  • Why Some See India's Budget as a Missed Opportunity